Company news

Stoke Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 28, 2022

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 9, 2022

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

August 24, 2022

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 31, 2022

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

May 1, 2022

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 6, 2022

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 4, 2022

Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

March 9, 2022

Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

February 27, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

January 9, 2022

Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

December 2, 2021

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

November 18, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

November 2, 2021

Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

September 21, 2021

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

September 20, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences in August

August 2, 2021

Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

May 17, 2021

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

May 3, 2021

Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom

March 29, 2021

Stoke Therapeutics to Present at Upcoming Investor Conferences

March 23, 2021

Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates

March 8, 2021

Stoke Therapeutics to Present at the Barclays Global Healthcare Conference

March 3, 2021

Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

December 3, 2020

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

December 3, 2020

Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

November 24, 2020

Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

November 23, 2020

Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

November 18, 2020

Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

November 8, 2020

Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

November 1, 2020

Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

October 6, 2020

Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

September 8, 2020

Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

August 25, 2020

Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

August 16, 2020

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

July 8, 2020

Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors

June 3, 2020

Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder

May 11, 2020

Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates

March 22, 2020

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference

February 23, 2020

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

Stoke Therapeutics Added to NASDAQ Biotechnology Index

December 22, 2019

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

December 7, 2019

Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

December 6, 2019

Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

November 25, 2019

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

November 24, 2019

Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

November 11, 2019

Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources

October 15, 2019

Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference

September 29, 2019

Stoke Therapeutics Added to Russell 2000 and 3000 Indexes

September 10, 2019

← Newer news releases

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.